Research Paper

ZNF521 which is downregulated by miR-802 suppresses malignant progression of Hepatocellular Carcinoma through regulating Runx2 expression

Nan Yang1, Liang Wang2, Tianxiang Chen2, Runkun Liu2, Zhikui Liu2, Lei Zhang3✉

1. Department of Infectious Diseases, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, 710061, China.
2. Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi’an Jiaotong University, No. 277 Yanta West Road, Xi’an 710061, China.
3. Department of Geriatric Surgery, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, 710061, China.

✉ Corresponding author: Dr Lei Zhang, Department of Geriatric Surgery, the First Affiliated Hospital of Xi’an Jiaotong University, No. 277 Yanta West Road, Xi’an 710061, China. E-mail: zanglei0519@xjtu.edu.cn.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.02.22; Accepted: 2020.07.18; Published: 2020.08.01

Abstract

Zinc finger protein 521 (ZNF521) plays an important role in the tumor development and process. However, its regulatory role in hepatocellular carcinoma (HCC) remains unclear. In this study, we demonstrated for the first time that ZNF521 mRNA and protein was down-regulated in HCC tissues and cell lines. Down-regulated ZNF521 expression was significantly associated with malignant prognostic features, including advanced TNM stage and large tumor size. For 5-year survival, ZNF521 served as a potential prognostic marker of HCC patients. Moreover, ZNF521 inhibited cell proliferation, colony formation and cell viability through Runx2 transcriptional inhibition and AKT phosphorylation pathway. Moreover, we demonstrated that ZNF521 expression was regulated by miR-802. In HCC tissues, MiR-802 has an inverse correlation with ZNF521 expression. In conclusion, we demonstrate for the first time that ZNF521 is down-regulated in HCC tissues and inhibits HCC growth through Runx2 transcriptional inhibition and AKT inactivation, which was regulated by miR-802, suggesting the potential therapeutic value for HCC.

Key words: ZNF521, hepatocellular carcinoma, Runx2, miR-802, proliferation

Introduction

Hepatocellular carcinoma (HCC) has been regarded as one of the leading causes of cancer-related death worldwide, especially in China [1]. Although there have been considerable improvements in current therapy interventions for HCC, the clinical therapeutic outcomes are still undesirable because of its unlimited proliferation and tumor metastasis [2]. Most of HCC patients are diagnosed at advanced stages due to lack of specific biomarkers and therapeutic targets, which leads to high mortality and poor prognosis [3]. Therefore, investigating the molecular mechanisms involved in HCC pathogenesis is important for the treatment.

Zinc finger protein 521 (EHZF/ZNF521) is a multi-functional transcription co-factor containing 30 zinc fingers and an N-terminal motif that binds to the nucleosome remodeling and histone deacetylase (NuRD) complex. ZNF521 plays a critical role in the homeostasis of the hematopoietic progenitor cell compartment, neuronal differentiation, bone formation and cancer progression [4-6]. ZNF521 can arrest the apoptosis and enhance the proliferation, migration, and invasion of gastric cancer cells via regulating miR-204-5p [7]. ZNF521 interacts with GLI1 and GLI2 to enhance the activity of the sonic hedgehog pathway in medulloblastoma [8]. Moreover, ZNF521 contributes to the clonogenic growth, migration and tumorigenicity of medulloblastoma cells [9]. ZNF521 promotes B-cell viability and cyclin D1 gene expression in a B cell culture system [10]. miR-9 promotes the neural differentiation of mouse bone marrow mesenchymal stem cells via...
targeting ZNF521 [11]. However, the potential role of ZNF521 in the pathogenesis of HCC has not been investigated.

In the present study, we found that ZNF521 was abnormally down-regulated both in HCC tissues and cells and that down-regulation was associated with malignant prognostic features and reduced survival of HCC patients. ZNF521 repressed the growth of HCC cells in vitro and in vivo. Furthermore, ZNF521 suppressed Runx2 transcriptional activity and regulated Runx2-related PI3K/AKT signaling pathways. miR-802 regulated ZNF521 expression via binding to its 3′UTR in HCC cells. Therefore, our data confirm that ZNF521 could be as a potential strategy for the diagnosis and treatment of HCC.

Materials and Methods

Clinical specimens

Hepatocellular carcinomas (HCC) tissues and adjacent non-tumor tissues (>2 cm from the margin of tumor) were obtained from patients who received surgical resection at the First Affiliated Hospital of Xi’an Jiaotong University. All the specimens were snap-frozen in liquid nitrogen and kept at -80°C after surgical removal. This study was approved by the Ethics Committee of this hospital. The written informed consents had been obtained from all patients before study.

Cell culture

All cell lines used in this study, including HCC cell lines (Hep3B, Huh7, SMMC-7721 and Bel-7402) and normal hepatic cell line (LO2) were obtained from the Institute of Biochemistry and Cell Biology (Chinese Academy of Sciences, Shanghai, China). Cell culture was performed in DMEM medium (Thermo Fisher, Grand Island, NY, USA) which containing 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO, USA) and 100 U/mL penicillin-streptomycin mixture (Beyotime Institute of Biotechnology, Haimen, China). The conditions for cell culture are as follows: a humidified atmosphere with 5% CO2 at 37°C.

RNA extraction and quantitative real-time PCR (qRT-PCR)

The total RNA from HCC cells and tissues was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. cDNA was synthesized by TaqMan miRNA reverse transcription (Applied Biosystems, Foster City, CA, USA) and a PrimeScript Reverse Transcriptase kit (Takara, Dalian, China). The relative expression of miR-802 and ZNF521 mRNA were quantified using miRNA-specific TaqMan miRNA Assay Kit (Applied Biosystems) and the SYBR Premix Ex Taq™ Kit (Takara, Shiga, Japan) in the Applied Biosystems 7500 Sequence Detection system. Primers for miR-802 and ZNF521 were obtained from Genecopoeia (Guangzhou, China).

Western blot

Immunohistochemical analysis status was performed as our previously publication [12]. Cell lysates were prepared using RIPA lysis Buffer (RIPA; Pierce, Rockford, IL). Then protease inhibitors were added into lysates. A bicinchoninic acid (BCA) kit (Beyotime Institute of Biotechnology, Shanghai, China) was used to determine protein concentration. Subsequently, protein was separated in 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) membrane and then transferred onto a polyvinylidene difluoride (PVDF) membrane (Millipore, Merck KGaA, Germany). Tris-buffered saline (TBS) containing 5% nonfat milk was used to block the membranes for an hour at room temperature. Thereafter, the membranes were incubated with specific primary antibodies at 4°C overnight. Subsequently, HRP-conjugated secondary antibody goat anti-rabbit IgG (1:2000, Abcam) was added and incubated for 2 h at room temperature. GAPDH was considered as the internal control. Bands signal were detected using the enhanced chemiluminescence (ECL; Millipore, Merck KGaA, Germany).

Immunohistochemistry (IHC) staining and scoring

Immunohistochemical analysis status was performed as our previously publication [13, 14].

Cell proliferation, cell cycle and viability detection

Cell Counting Kit-8 (CCK8) reagents (Dojindo, Kumamoto, Japan), EdU and colony formation were carried as described previously [14-16].

Luciferase reporter assay

The sequence of ZNF521 3′-UTR containing the putative miR-802 binding region was amplified from human genomic DNA. Then the sequence was cloned into pGL3 luciferase reporter vector (Promega, Madison, WI, USA). The potential miR-802 binding sites were mutated by the Quick-change site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA). The wild type (wt) ZNF521 3′-UTR vector or mutant (mt) ZNF521 3′-UTR vector and miR-802 mimics or miR-802 inhibitors were co-transfected into Hep3B cells by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The luciferase activity was measured using Dual-Luciferase Reporter Assay
System (Promega, Madison, WI, USA) under luminometer (Berthold Detection System, Pforzheim, Germany), and luciferase activity was normalized to Renilla activity.

**In vivo experiments**

Four-to-six-week-old male BALB/c nude mice (Centre of Laboratory Animals, The Medical College of Xi’an Jiaotong University, Xi’an, China) were used to establish the nude mouse xenograft model. Hep3B (5×10⁶) cells that were transfected with ZNF521 overexpression vectors or control vectors were mixed in 150 µL of Matrigel and were inoculated subcutaneously into the flank of nude mice. The tumor volume for each mouse was determined by measuring two of its dimensions and then calculated as tumor volume = length × width × width/2. After 3 weeks, the mice were sacrificed by cervical dislocation under anesthesia with ether and the xenograft tumor tissue was explanted for examination. Animal protocols were approved by the Institutional Animal Care and Use Committee of Xi’an Jiaotong University.

**Statistical analysis**

In this study, statistical analyses were performed with SPSS 17.0 software (Abbott Laboratories, Chicago, IL). Data represent mean ± standard deviation (SD) of more than two independent experiments. A two-sided Student’s t-test and one-way ANOVA were separately used to compare the statistical differences. The Kaplan-Meier method was used to estimate the overall survival (OS) of HCC patients with high or low level of ZNF521. Difference was considered statistically significant when P < 0.05.

**Results**

**ZNF521 is down-regulated in HCC tissues and cells**

To determine the function of ZNF521 in HCC progression, the expression of ZNF521 mRNA and protein was determined by qRT-PCR and western blot. The results revealed that ZNF521 mRNA and protein was robustly reduced in HCC tissues relative to that in adjacent non-tumor tissues (P < 0.05, Figure 1A-B). Moreover, IHC staining assays showed that ZNF521 IHC scores in HCC tissues was down-regulated compared to normal tissues (P < 0.05, Figure 1C). In HCC cells, our results showed that ZNF521 was decreased in HCC cells compared with normal hepatic cells LO2 (P < 0.05, Figure 1D). Therefore, we demonstrated that ZNF521 plays a role as a tumor suppressor in HCC progression.

**ZNF521 expression is associated with malignant clinic-pathological characteristics**

To clarify the role of ZNF521 in clinical, we divided the HCC patients as different subgroups according to the median value as a cutoff. The down-regulated ZNF521 was significantly associated with large tumor size (P = 0.026) and advanced TNM stage (P = 0.018, Table 1). Kaplan-Meier survival analysis curve showed that low ZNF521 HCC patients had a shorter overall survival (OS) and disease-free survival (DFS) in HCC patients (P = 0.0003, 0.0004, respectively, Figure 1E). Moreover, in other cohort HCC patients, 182 patients with ZNF521 high expression and 182 patients with ZNF521 low expression were analyzed in GEPIA (P < 0.05, Figure 1F). These data suggest that ZNF521 is a potential prognostic biomarker in HCC patients.

**Table 1. Clinical correlation of ZNF521 expression in HCC (n = 101)**

| Clinical parameters | Cases (n) | Expression level | P value (P < 0.05) |
|---------------------|-----------|------------------|-------------------|
| Age (years)         |           |                  |                   |
| < 60 years          | 65        | 35               | 0.150             |
| 60+ years           | 36        | 14               |                   |
| Gender              |           |                  |                   |
| Male                | 80        | 40               | 0.56              |
| Female              | 21        | 9                |                   |
| Tumor size (cm)     |           |                  |                   |
| < 5 cm              | 72        | 40               | 0.026*            |
| ≥ 5 cm              | 29        | 9                |                   |
| Tumor number        |           |                  |                   |
| solitary            | 84        | 42               | 0.507             |
| multiple            | 17        | 7                |                   |
| Edmonson            |           |                  |                   |
| I+II                | 22        | 13               | 0.382             |
| III+IV              | 78        | 36               |                   |
| TNM stage           |           |                  |                   |
| I+II                | 76        | 42               | 0.018*            |
| III+IV              | 25        | 7                |                   |
| Vascular infiltration|          |                  |                   |
| Present             | 16        | 7                | 0.678             |
| Absent              | 85        | 42               |                   |
| AFP                 |           |                  |                   |
| < 400 ng/ml         | 24        | 9                | 0.216             |
| ≥ 400 ng/ml         | 77        | 40               |                   |
| HBsAg               |           |                  |                   |
| positive            | 91        | 43               | 0.444             |
| negative            | 10        | 6                |                   |

HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis. *Statistically significant.

**ZNF521 inhibits cell proliferation, colony formation and promotes apoptosis in HCC**

To clarify the function of ZNF521 in HCC, we performed gain- and loss-of function assays by transfecting respective vectors in Hep3B and Huh7 whose endogenous ZNF521 was lowest and highest expression in HCC cell lines (P < 0.05, Figure 2A). We used Edu, colony formation and CCK-8 assay showed that ZNF521 overexpression significantly inhibited...
cell proliferation, colony formation and cell viability in Hep3B cells ($P < 0.05$, Figure 2B-D). Conversely, ZNF521 knockdown showed opposite effect on Huh7 cells ($P < 0.05$, Figure 2B-D). In addition, western blot revealed that ZNF521 regulated Cyclin D1 and p21 expression ($P < 0.05$, Figure 2E). These data proposed that ZNF521 hindered cell growth in HCC cells in vitro.

**ZNF521 inhibits HCC growth in vivo**

To further explore the function of ZNF521 on tumor growth in vivo, we used the subcutaneous tumor model and the data showed that ZNF521 overexpression significantly inhibited the tumor growth than control cells in mice ($P < 0.05$, Figure 3A). Moreover, we used the Ki67 and TUNEL staining to evaluate the proliferative and apoptotic rate in vivo. ZNF521 overexpression decreased Ki67 positive staining rate and increased the number of apoptotic cells for TUNEL positive staining ($P < 0.05$, Figure 3B-C). These results indicated that ZNF521 suppressed tumor growth in vivo.

**ZNF521 antagonizes Runx2 transcriptional activity in HCC cells**

Runt-related transcription factor 2 (Runx2) is a key promoter of HCC [17]. We examined the effects of ZNF521 on Runx2-induced of Runx2-luciferase reporter genes in Hep3B. As shown in Figure 4A, ZNF521 strongly repressed Runx2 transcriptional activity ($P < 0.05$, Figure 4A). Moreover, ZNF521 overexpression inhibited Runx2 mRNA and protein expression while ZNF521 knockdown increased Runx2 mRNA and protein expression ($P < 0.05$, Figure 4B-C). To confirm that Runx2 mediated the effects on ZNF521 on HCC cells, we reversed Runx2

---

**Figure 1. ZNF521 is significantly down-regulated in HCC tissues and cell lines.** (A) Relative ZNF521 mRNA expression levels in HCC tissues and matched adjacent nontumor tissues were determined by qRT-PCR. (B) Representative Western blot analysis of ZNF521 expression in the HCC (T) and nontumor tissues (NT) was shown. (C) Representative images of IHC staining of ZNF521 in HCC and adjacent non-tumor tissues. Comparing differences in the expression level of ZNF521 protein (D) between HCC cell lines with the immortalized normal hepatic cell LO2. (E) HCC patients with lower expression of ZNF521 had worse overall survival and disease-free survival. (F) Cases with high/low ZNF521 expression were analyzed. n = three repeats with similar results; *$P < 0.05$. 

http://www.jcancer.org
expression in HCC cells ($P < 0.05$, Figure 4D). Runx2 reversed the effects of ZNF521 on HCC cells ($P < 0.05$, Figure 4E-G). Runx2 was up-regulated in HCC compared to adjacent non-tumor tissues ($P < 0.05$, Figure S1). These results revealed that ZNF521 repressed Runx2 transcriptional activity and exerted its effects at least partly through Runx2.

Figure 2. ZNF521 inhibited cell proliferation, colony formation and viability in vitro. (A) Hep3B and Huh7 cells that were transfected with different vectors were subjected to western blot for ZNF521 expression. ZNF521 overexpression inhibited cell proliferation (B), colony formation (C) and viability (D) in Hep3B cells, while ZNF521 knockdown promoted proliferation (B), cell colony formation (C) and viability (D) in Huh7 cells. (E) Western blot analysis of protein Cyclin D1 and p21 expression in the presence and absence of ZNF521. *$P<0.05$. EV, empty vectors. n=three independent experiments; *$P<0.05$.

Figure 3. ZNF521 inhibited tumor growth in vivo. (A) Tumor growth curve revealed that ZNF521 overexpression significantly inhibited tumor growth in vivo. (B) Tumor nodules were subjected to immunohistochemical staining for Ki-67 assays and (C) TUNEL and quantitative analysis. Scale bar: 70 µm; *$P<0.05$. 

---

http://www.jcancer.org
**AKT phosphorylation acts downstream of ZNF521 to mediate its effects on HCC**

AKT phosphorylation signaling was involved in HCC development [18]. We demonstrated that ZNF521 overexpression inhibited AKT phosphorylation while ZNF521 knockdown increased the AKT phosphorylation (P < 0.05, Figure 5A). Moreover, we inquired whether AKT phosphorylation is necessary for ZNF521-induced effects on HCC by using the AKT inhibitor MK2206. We found that ZNF521 knockdown induced cell proliferation, colony formation and cell viability of HCC cells was significantly reversed by the addition of MK2206 (P < 0.05, Figure 5B-E). These data suggest that AKT signaling is necessary for ZNF521-induced effects of HCC cells.

**ZNF521 expression is regulated by miR-802**

Growing evidences indicated that microRNAs play crucial roles in cancer development and progression by targeting mRNAs for degradation or translational repression [19]. To investigate the upstream that ZNF521 was down-regulated, we searched the database miRNA.org, TargetScan and PicTar to predict that miR-802 bind to the 3'UTR of ZNF521 (Figure 6A). We used luciferase reporter assays to show that miR-802 overexpression markedly decreased while miR-802 knockdown increased the luciferase activity of HCC cells with wild-type ZNF521 3'UTR (P < 0.05, Figure 6B). However, the activity in mutant-type ZNF521 3'UTR had no change (Figure 6B). Moreover, miR-802 overexpression significantly inhibited while miR-802 knockdown...
promoted ZNF521 mRNA and protein in HCC cells ($P < 0.05$, Figure 6C-D). In HCC tissues, our results showed that miR-802 was up-regulated in HCC tissues compared to adjacent non-tumor tissues ($P < 0.05$, Figure 6E), which was consistent with previous studies [20]. We also confirmed an inverse correlation between ZNF521 mRNA and miR-802 in HCC tissues ($r=-0.7223$, $P < 0.05$, Figure 6F). Moreover, miR-802 overexpression significantly promoted cell proliferation, colony formation and cell viability in Huh7 cells ($P < 0.05$, Figure S2A-D). Conversely, miR-802 knockdown showed opposite effects in Hep3B cells ($P < 0.05$, Figure S2A-D). In conclusion, we demonstrated that miR-802 regulated ZNF521 expression in HCC tissues.

**Discussion**

Zinc finger structures, forming a total of 6 zinc finger clusters, participate in multiple signaling pathways and regulate the downstream target genes, thus regulating various biological processes such as hematopoietic differentiation, cell proliferation and autophagy [21]. ZNF521 was characterized as potent inhibitor of EBF1 and contributed to the development of B-cell leukemias. ZNF521 was a target gene and key effector of parathyroid hormone-related peptide signaling in growth plate chondrocytes [22]. In this research, we demonstrated that ZNF521 was down-regulated in HCC tissues and cells for the first time. In clinical data, we showed that down-regulated ZNF521 was significantly associated with large tumor size and advanced TNM stage. Moreover, ZNF521 down-regulation showed a worse prognosis for 5-year OS and DFS in HCC patients, which was consistent in other cohort HCC patients. These findings confirmed the fundamental role of ZNF521 in HCC development.

To investigate the biological effects of ZNF521 in HCC, we used the gain- and loss-of-function experiment to clarify that ZNF521 significantly inhibited cell proliferation, colony formation and cell viability in HCC cells in vitro and in vivo. Mechanically, we confirmed that ZNF521 exerted its effects by regulating Runx2 expression and repressed

![Figure 5. AKT phosphorylation acts downstream of ZNF521 to mediate the effects on HCC cells.](image)

![Figure 6. ZNF521 is identified as a direct target of miR-802 in HCC.](image)
its transcriptional activity. Runx2 was involved in osteoblastic differentiation, skeletal morphogenesis and cancer progression [23-25]. Runx2 overexpression promoted CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis [26]. Runx2 plays an oncogenic role in esophageal carcinoma by activating the PI3K/AKT and ERK signaling pathways [27]. Runx2 promoted HCC cell migration and invasion by regulating MMP9 expression [17]. Here, we identified that Runx2 mediated the function of ZNF521 on HCC cells. Moreover, PI3K/AKT signaling was proposed as a vital mechanism that regulates the initial steps of metastatic progression of cancer [12, 28]. Our results showed that AKT pathway abolished the inhibitory effect of ZNF521 on HCC cells. Taken together, these data demonstrated the suppressive effect of ZNF521 was mediated by inhibiting AKT phosphorylation pathway in HCC.

Previous studies showed that miRNA can specifically induce the degradation of target gene mRNA and inhibit the translation of gene [29, 30]. Here, we confirmed that miR-802 could bind with ZNF521 3’UTR. miR-802 negatively regulated the expression of ZNF521 mRNA and protein in HCC cells. Previous studies reported that miR-802 accelerates hepatocarcinoma growth by targeting Runx3 [20]. High blood miR-802 is associated with poor prognosis in HCC patients by regulating DNA damage response 1 (REDD1)-mediated function of T cells [31]. miR-802 inhibits cell proliferation and induces apoptosis in human laryngeal cancer by targeting Camp-regulated phosphoprotein 19 [32]. These data further confirm that miR-802 exerted its effects was cell-specific [33, 34]. Here, we demonstrated that miR-802 promoted HCC growth. In conclusion, these data suggest that ZNF521 was a downstream target of miR-802 in HCC.

In summary, we reported for the first time that ZNF521 was down-regulated in HCC tissues and cells and its down-regulation was associated with malignant clinical features and unfavorable prognosis. We confirmed that ZNF521 inhibited cell proliferation, colony formation and cell viability through Runx2 transcriptional inhibition and AKT phosphorylation pathway. Moreover, miR-802 regulated ZNF521 expression in HCC cells. These data indicated that ZNF521 was an important biomarker of HCC progression and a novel and attractive therapeutic target for HCC treatment.

Supplementary Material
Supplementary figures and tables. http://www.jcancer.org/v11p5831s1.pdf

Acknowledgements
This study was supported by grants from Natural Science Basic Research Program of Shaanxi (Program No. 2020JQ-498; 2020JQ-496). Institutional Foundation of the First Affiliated Hospital of Xi’an Jiaotong University (2019QN-24). Key Research and Development Program of Shaanxi (Program No. 2020SF-061).

Competing Interests
The authors have declared that no competing interest exists.

References
1. Chen W, Zheng R, Baade PD, Zhang S, Zhen H, Bray F, et al. Cancer statistics in China, 2015. CA: a cancer journal for clinicians. 2016; 66: 115-32.
2. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018; 391: 1301-14.
3. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nature reviews Gastroenterology & hepatology. 2010; 7: 448-58.
4. Hesse E, Kiviranta I, Wu M, Saito H, Yamana K, Correa D, et al. Zinc finger protein 521, a new player in bone formation. Annals of the New York Academy of Sciences. 2010; 1192: 32-7.
5. Wu M, Hesse E, Morvan F, Zhang JP, Correa D, Rowe GC, et al. Zfp521 antagonizes Runx2, delays osteoblast differentiation in vitro, and promotes bone formation in vivo. Bone. 2009; 44: 528-36.
6. Yamasaki N, Miyazaki K, Nagamachi A, Koller R, Oda H, Miyazaki M, et al. Identification of Zfp521/ZNF521 as a cooperative gene for E2A-HLF to develop acute B-lineage leukemia. Oncogene. 2010; 29: 1963-70.
7. Li Q, Xueqin C, Xianfang R. Finger Protein 521 Negatively Regulated by MicroRNA-204-5p. Promotes Proliferation, Motility and Invasion of Gastric Cancer Cells. Technology in cancer research & treatment. 2019; 18: 153303818764763.
8. Scicchitano S, Giordano M, Lucchino V, Montalcini Y, Chiarella E, Aloisi A, et al. The stem cell-associated transcription co-factor, ZNF521, interacts with GLI1 and GLI2 and enhances the activity of the Sonic hedgehog pathway. Cell death & disease. 2019; 10: 715.
9. Spinaz, Filocamo G, Iaccino E, Scicchitano S, Lupia M, Chiarella E, et al. Critical role of zinc finger protein 521 in the control of growth, clonogenicity and tumorigenic potential of medulloblastoma cells. Oncotarget. 2013; 4: 1280-92.
10. Al Dallal S, Wolton K, Hentges KE. Zfp521 promotes B-cell viability and cyclin D1 gene expression in a B cell culture system. Leukemia research. 2016; 46: 10-7.
11. Han R, Kan Q, Sun Y, Wang S, Zhang G, Peng T, et al. miR-9 promotes the neural differentiation of mouse bone marrow mesenchymal stem cells via targeting zinc finger protein 521. Neuroscience letters. 2012; 515: 147-52.
12. Liu Z, Wang Y, Dou C, Xu M, Sun L, Wang L, et al. Hypoxia-induced up-regulation of VASP promotes invasiveness and metastasis of hepatocellular carcinoma. Theranostics. 2018; 8: 4649-63.
13. Liu Z, Wang Y, Wang L, Yao B, Sun L, Liu R, et al. Long non-coding RNA AGAP2-AS1, functioning as a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma. Journal of experimental & clinical cancer research: CR. 2019; 38: 194.
14. Liu Z, Wang Y, Dou C, Sun L, Li Q, Wang L, et al. MicroRNA-1468 promotes tumour progression by activating PPAR-gamma-mediated AKT signalling in human hepatocellular carcinoma. Journal of experimental & clinical cancer research: CR. 2018; 37: 49.
15. Yang N, Chen J, Zhang H, Wang X, Yao H, Peng Y, et al. LncRNA OIPS-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma. Cell death & disease. 2017; 8: e2957.
16. Liu Z, Dou C, Yao B, Xu M, Ding L, Wang Y, et al. Fts non coding RNA-derived miR-545 promotes cell proliferation by targeting RIG-I in hepatocellular carcinoma. Oncotarget. 2016; 7: 25380-65.
17. Wang Q, Yu W, Huang T, Zhu Y, Huang C. RUNX2 promotes hepatocellular carcinoma cell migration and invasion by upregulating MMP9 expression. Oncology reports. 2016; 36: 2777-84.
18. Li Q, Wang C, Wang Y, Sun L, Liu Z, Wang L, et al. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways. Journal of experimental & clinical cancer research: CR. 2018; 37: 231.
19. Wang L, Sun L, Wang Y, Yao B, Liu R, Chen T, et al. miR-1204 promotes hepatocellular carcinoma progression through activating MAPK and...
c-Jun/AP1 signaling by targeting ZNF418. International journal of biological sciences. 2019; 15: 1514-22.

20. Ni M, Zhao Y, Zhang WJ, Jiang YJ, Fu H, Huang F, et al. microRNA-802 accelerates hepatocellular carcinoma growth by targeting RUNX3. Journal of cellular physiology. 2020; 11: 151-59.

21. Hesse E, Saito H, Kiviranta R, Correa D, Yamana K, Neff L, et al. Zfp521 controls bone mass by HDAC3-dependent attenuation of Runx2 activity. The Journal of cell biology. 2010; 191: 1271-83.

22. Correa D, Hesse E, Serivatanaachai D, Kiviranta R, Saito H, Yamana K, et al. Zfp521 is a target gene and key effector of parathyroid hormone-related peptide signaling in growth plate chondrocytes. Developmental cell. 2010; 19: 533-46.

23. Yamada D, Fujikawa K, Kawabe K, Furuta T, Nakada M, Takarada T. RUNX2 Promotes Malignant Progression in Glioma. Neurochemical research. 2019; 43: 2047-54.

24. Villarsaneva F, Araya H, Briceno P, Varela N, Stevenson A, Jerez S, et al. The cancer-related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis. Journal of cellular physiology. 2019; 234: 13659-79.

25. Mevel R, Draper JE, Lie ALM, Kouskoff V, Lacaud G. RUNX transcription factors: orchestrators of development. Development. 2019; 17: 146-65.

26. Bai Y, Yang Y, Yan Y, Zhong J, Blee AM, Pan Y, et al. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis. Theranostics. 2019; 9: 3459-75.

27. Lu H, Jiang T, Ren K, Li ZL, Ren J, Wu G, et al. RUNX2 Plays An Oncogenic Role in Esophageal Carcinoma by Activating the PI3K/AKT and ERK Signaling Pathways. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2019; 49: 217-25.

28. Dou C, Zhou Z, Xu Q, Liu Z, Zeng Y, Wang Y, et al. Hypoxia-induced TUFT1 promotes the growth and metastasis of hepatocellular carcinoma by activating the Ca(2+)/PI3K/AKT pathway. Oncogene. 2019; 38: 1239-55.

29. Sun L, Wang L, Chen T, Yao B, Wang Y, Li Q, et al. microRNA-1914, which is regulated by lncRNA DUXAP10, inhibits cell proliferation by targeting the GPR39-mediated PI3K/AKT/mTOR pathway in HCC. Journal of cellular and molecular medicine. 2019; 23: 8292-304.

30. Yao B, Li Y, Wang L, Chen T, Niu Y, Liu Q, et al. MicroRNA-3194-3p inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by decreasing Wnt/beta-catenin signaling through targeting BCL9. Artificial cells, nanomedicine, and biotechnology. 2019; 47: 3885-95.

31. Jiang C, Liu X, Wang M, Lv G, Wang G. High Blood miR-802 Is Associated With Poor Prognosis in HCC Patients by Regulating DNA Damage Response I (REDD1)-Mediated Function of T Cells. Oncology research. 2019; 27: 1025-34.

32. Ye H, Jin Q, Wang X, Li Y. MicroRNA-802 Inhibits Cell Proliferation and Induces Apoptosis in Human Laryngeal Cancer by Targeting cAMP-Regulated Phosphoprotein 19. Cancer management and research. 2020; 12: 419-30.

33. Wang Y, Cao J, Zhang S, Sun L, Nan Y, Yao H, et al. MicroRNA-802 induces hepatitis B virus replication and replication through regulating SMARCE1 expression in hepatocellular carcinoma. Cell death & disease. 2019; 10: 783.

34. Zhang Q, Lv R, Guo W, Li X. microRNA-802 inhibits cell proliferation and induces apoptosis in human cervical cancer by targeting serine/arginine-rich splicing factor 9. Journal of cellular biochemistry. 2019; 120: 10370-9.